EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 305 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer June 24, 2020 NHS ‘understaffed and underequipped’ to tackle cancer, say 3 in 4... May 25, 2022 Immunotherapy Drug Cemiplimab Approved for Advanced Squamous Cell Skin Cancer October 19, 2018 See How These Food Banks Are Putting Your Feed Thy Neighbor... February 9, 2021 Load more HOT NEWS Immunotherapy after Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer First-Line Treatment with Ribociclib plus Letrozole Shows a Significant Overall Survival... FDA Approves Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant... Colorectal Cancer Screening: The Silver Lining
